By Marco Moci1, MD, Antonio Ciacciarelli2, MD and Barbara Casolla3, MD, PhD
Twitter: @m_moci; @a_ciacciarelli; @BarbaraCasolla
1 Department of Neurosciences, Institute of Neurology. Catholic University of the Sacred Heart. University Hospital “IRCCS Fondazione Policlinico A. Gemelli”, Rome, Italy
2 Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
3 Stroke Unit, CHU Pasteur 2, UR2CA-URRIS Neurology, Nice Cote d’Azur University, Nice, France
Inflammation plays a central and complex role in the pathogenesis of cerebrovascular diseases. Indeed, at early stages of the post-ischemic molecular cascade, activated intravascular leucocytes and proinflammatory mediators from endothelium and microglia contribute to brain damage, and, later on, they are pivotal for brain repair 1. In the clinical setting, a growing body of evidence suggests that systemic inflammation, including blood levels of circulating pro-inflammatory cytokines, is associated to higher risk of cerebrovascular diseases and worse clinical outcomes after in acute ischemic stroke (AIS) 2. Over the years, several cytokines, including interleukin (IL) 1-beta, IL-6, IL-10, IL-17, and IL-8 have been identified as peripheral blood prognostic markers, and have been associated to worse long-term functional and cognitive outcomes after an AIS 3,4.
In cardiology, the CANTOS trials provided the first evidence on antibody targeting interleukin-1β (canakinumab) for secondary prevention after myocardial infarction 5. Results showed a significantly lower risk of recurrent ischemic cardiovascular events in the interventional arm compared to placebo, however, canakinumab was associated with higher risk of fatal infections. The recent randomised controlled trial (RCT) on colchicine (COLCOT) found a significantly lower risk of ischemic cardiovascular events than placebo in patients with a recent myocardial infarction6. Results of COLCOT were confirmed by another RCT (LoDoCo2), and a following meta-analysis showed that the risk of stroke almost halves in patients with coronary artery disease (CAD) treated with colchicine7,8. Accordingly, new 2021 European Society of Cardiology (ESC) guidelines recommend low-dose of colchicine (0.5 mg daily) for secondary prevention of cardiovascular diseases, particularly if other risk factors are insufficiently controlled or if recurrent cardiovascular disease events occur under optimal therapy (Class IIb, Level A) 9.
In the field of stroke medicine, many RCTs were conducted on patients with AIS to prove the benefit of anti-inflammatory and immunomodulatory drugs on functional outcome. Recently, SCIL-STROKE trial tested subcutaneous IL-1 receptor antagonist (IL-1Ra) in patients with AIS and found that IL-1Ra was safe but without benefit on 3-months clinical outcome 10. ACTION II trial evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with AIS but patients receiving natalizumab had worse outcomes 11. A double-blind, placebo-controlled, randomised, phase Ib/IIa clinical ongoing study is evaluating ApTOLL, a Toll-like receptor 4 (TLR4) antagonist in patients with large vessel occlusions (NCT04734548).
Regarding secondary prevention, different RCTs are ongoing. The CONVINCE study (NCT02898610), is currently investigating the efficacy of low-dose colchicine on reducing stroke recurrence or death after AIS or transient ischemic attacks of non-cardioembolic origin and the CIAFS-1 study (NCT02282098) is testing colchicine in patients with atrial fibrillation. Finally, the ZEUS trial is studying Ziltivekimab (a human monoclonal antibody against IL-6) in patients with cardiovascular and chronic kidney disease (NCT05021835).
The post-stroke inflammatory response still represents a potential target for improving acute and secondary prevention strategies. Stroke treatments are always a matter of time: despite the negative results of previous RCTs on immunomodulatory drugs in the acute phase, there are reasons to be optimistic for the future. Challenging the identification of an inflammatory “window” will probably allow a more accurate and personalised patients’ selection, both imaging- and biologically based.
1 Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics 2016; 13: 661–70.
2 Chamorro Á, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006; 37: 291–3.
3 McCabe JJ, O’Reilly E, Coveney S, et al. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis. Eur Stroke J 2021; 6: 62–71.
4 Zeng L, Liu J, Wang Y, et al. Cocktail blood biomarkers: Prediction of clinical outcomes in patients with acute ischemic stroke. Eur Neurol 2013; 69: 68–75.
5 Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377: 1119–31.
6 Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381: 2497–505.
7 Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383: 1838–47.
8 Samuel M, Tardif JC, Bouabdallaoui N, et al. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Can J Cardiol 2021; 37: 776–85.
9 Visseren FLJ, MacH F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceDeveloped by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With th. Eur Heart J 2021; 42: 3227–337.
10 Smith CJ, Hulme S, Vail A, et al. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial. Stroke 2018; 49: 1210–6.
11 Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology 2020; 95: e1091–104.